SCHEMBL13401451

SCHEMBL13401451

COC(=O)c1ccc(C(O)(O)O)o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.55
MEN1 O00255 2/20 0.51
CYP1A2 P05177 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP2C19 P33261 1/20 0.51
ALDH1A1 P00352 3/20 0.50
TSHR P16473 2/20 0.47
NPSR1 Q6W5P4 1/20 0.46
LMNA P02545 3/20 0.45
KDM4E B2RXH2 2/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
SETD7 Q8WTS6 1/20 0.45
POLB P06746 1/20 0.45
GAA P10253 1/20 0.45
CYP2C9 P11712 1/20 0.45
HPGD P15428 1/20 0.45
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPT P10636 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7366271 0.87 HTT (0.53) HTTMEN1CYP1A2KMT2ACYP2C19
SCHEMBL3229079 0.85 HTT (0.55) HTTMEN1CYP1A2KMT2ACYP2C19
SCHEMBL12019021 0.85 HTT (0.55) HTTMEN1CYP1A2KMT2ACYP2C19
SCHEMBL69791 0.81 HTT (0.69) HTTMEN1CYP1A2KMT2ACYP2C19
SCHEMBL21981938 0.79 HTT (0.67) HTTMEN1CYP1A2KMT2ACYP2C19
SCHEMBL24479151 0.79 ALDH1A1 (0.53) HTTMEN1CYP1A2KMT2ACYP2C19
SCHEMBL12017375 0.79 MEN1 (0.50) HTTMEN1CYP1A2KMT2ACYP2C19
SCHEMBL4197412 0.78 HTT (0.47) HTTMEN1CYP1A2KMT2ACYP2C19
Ethylene SCHEMBL22615238 0.77 HTT (0.64) HTTMEN1CYP1A2KMT2ACYP2C19
Propane SCHEMBL28412029 0.75 HTT (0.68) HTTMEN1CYP1A2KMT2ACYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9757375-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2017-09-12 US disclosed
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-11-05 US disclosed
US-9073896-B2 Compounds that inhibit human DNA ligases and methods of treating cancer UNIVERSITY OF MARYLAND, BALTIMORE (US) 2015-07-07 US disclosed
US-20140113891-A1 Compounds that inhibit human DNA ligases and methods of treating cancer NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-04-24 US disclosed
US-8445537-B2 Compounds that inhibit human DNA ligases and methods of treating cancer STC.UNM (US) 2013-05-21 US disclosed
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099683-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 HTT 1828/4885MEN1 2792/4885CYP1A2 4157/4885
US-20150313898-A1 COMPOUNDS THAT INHIBIT HUMAN DNA LIGASES AND METHODS OF TREATING CANCER LIG1, LIG4, LIG3 HTT 1828/4885MEN1 2792/4885CYP1A2 4157/4885
US-20140113891-A1 Compounds that inhibit human DNA ligases and methods of treating cancer LIG1, LIG4, LIG3 HTT 1828/4885MEN1 2792/4885CYP1A2 4157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.